secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2023-12-21T23:59:59+00:00
Accession:  0001193125-23-300417
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium completes EQ101 Phase 2 enrollment for alopecia areata; advances EQ302 over EQ102
--------------------------------------------------------------------------------

- Completed enrollment of 36 patients in EQ101 Phase 2 study for alopecia areata; topline data expected Q2 2024.
- Baseline: mean SALT score of 76; 50% severe (SALT 50-94), 33% very severe (SALT >95%).
- 75% of patients had prior treatments; 11 received oral treatments including JAK inhibitors.
- EQ302 oral multi-cytokine inhibitor of IL-15 & IL-21 to be advanced for GI/skin diseases instead of EQ102.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000119312523300417/0001193125-23-300417-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000119312523300417/d575238d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-300417

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer